<DOC>
	<DOCNO>NCT02562131</DOCNO>
	<brief_summary>Simultaneous PET/MRI potential improve detection accuracy recurrent prostate cancer , since combine excellent soft-tissue contrast MRI high molecular sensitivity PET single imaging session . The aim study evaluate sensitivity specificity simultaneous 18F-Fluciclovine PET/MRI detection recurrent prostate cancer .</brief_summary>
	<brief_title>PET-MR-PSA Prostate Cancer Recidive Study</brief_title>
	<detailed_description>The patient follow standard treatment follow-up PET/MRI exam , determine patient 's treat urologist and/or oncologist . Data histopathology , clinical follow-up follow-up imaging collect establish reference standard defines presence absence disease patient . The imaging finding compare reference standard ass sensitivity specificity . The diagnostic accuracy combine PET/MRI MRI-only ( current clinical standard ) compare .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<criteria>criterion biochemical relapse accordance European Association Urology ( EAU ) guideline prostate cancer must fulfil ( two consecutive measurement PSA &gt; 0.2 ng/ml follow radical prostatectomy PSA &gt; 2.0 ng/ml nadir follow definitive radiotherapy ) potential candidate salvage treatment base age comorbidity . general contraindication PET/MRI exam ( pacemaker , aneurysm clip , form metal body , severe claustrophobia ) impair renal function define estimate glomerular filtration rate ( eGFR ) &lt; 30 ml/min/1.73 m2</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>PET-MR</keyword>
	<keyword>recidive</keyword>
	<keyword>PET/MR imaging</keyword>
	<keyword>18F-Fluciclovine</keyword>
	<keyword>radical treatment</keyword>
	<keyword>recurrence</keyword>
</DOC>